1. A method of determining an association between a sensory context and a user indication, the method comprising:
determining a first sensory context version and a second sensory context version using a first sensory modality, the first and the second sensory context version characterized by a first and a second location parameter, respectively;
determining a third sensory context version using a second sensory modality, the third sensory context version characterized by a third location parameter;
when (i) the third sensory context version occurs within a first time interval from an occurrence of the first sensory context version, and (ii) the third location parameter matches the first location parameter, signifying a sensory context occurrence;
when the user indication occurs within a second time interval from the sensory context occurrence, updating association information related to the association; and
storing the association information in a nonvolatile computer-readable medium;
wherein:
the stored association information is configured to enable automatic retrieval of user information related to the user indication based on a subsequent sensory context occurrence.
2. The method of claim 1, wherein:
the first sensor modality is characterized by oscillations of a first type of wave;
the second sensor modality is characterized by oscillations of a second type of wave; and
the second type of wave being of a different physical nature compared to the first type of wave.
3. The method of claim 2, wherein:
individual ones of the first type of wave and the second type of wave are mechanical waves or electromagnetic waves.
4. The method of claim 1, wherein:
the first type of wave and the second type of wave comprise electromagnetic waves oscillating in non-overlapping frequency bands; and
the first time interval or second time interval is selected from the range between 1 second and 5 seconds.
5. The method of claim 1, wherein:
the association information comprises a look up table comprising a plurality of entries, each individual entry of the plurality of entries is configured to characterize an occurrence of a given context and a given user indication; and
updating the association information comprises incrementing a value of the look up table that is associated with the sensory context occurrence and the user indication.
6. A computerized method for providing a remote control command to a computerized device based on a sequence of digital images, the method comprising:
determining a discrepancy measure based on a comparison of pixels of a current image of the sequence of digital images to a reference image;
determining a salient feature based on an analysis of the discrepancy measure, the salient feature being associated with a portion of pixels within the current image;
based on an existence of a previously established association between an occurrence of a user indication associated with an action by the computerized device and the salient feature, automatically transmitting a command to the computerized device, the command configured to cause the computerized device to execute the action.
7. The method of claim 6, where the sequence of digital images is received from a camera that is remote from the computerized device.
8. The method of claim 7, further comprising storing information related to one or more user indications, each user indication corresponding to a state;
wherein:
the command is associated with the one or more user indications; and
the automatic transmission of the command is based on an occurrence of the state.
9. The method of claim 8, wherein
wherein the state of the computerized device comprises a position of the computerized device in an environment of the computerized device.
10. The method of claim 6, wherein
a state comprises a parameter characterizing environment external to the computerized device; and
the parameter is configured to convey one or more of a position, a gesture, or a movement of a person.
11. The method of claim 6, wherein,
the salient feature comprises a representation of a user body portion; and
the reference image comprises an image acquired prior to the current image without the representation of the user body portion.
12. The method of claim 11, wherein, the reference image is based on a low pass filter operation on a plurality of images from the sequence of digital images, where the individual ones of the plurality of images precede the current image.
13. The method of claim 12, wherein:
the discrepancy measure comprises a difference image determined based on a pixel wise difference operation between the current image and the reference image, and the difference image comprises one or more background pixel values and two or more areas of pixels having values different from the one or more background pixel values; and
the analysis of the discrepancy measure comprises a winner takes all process configured to select one area from the two or more areas.
14. The method of claim 13, wherein: the winner takes all process is configured based on determining, for a given area of the two or more areas, one or more of a total number of pixels within the given area, a sum of values of pixels within the given area, a sum of deviations from a reference pixel value of a plurality of values of pixels within the given area.
15. The method of claim 6, wherein transmission of the command comprises an infrared signal transmission.
16. The method of claim 6, wherein transmission of the command comprises a radio frequency signal transmission.
17. The method of claim 6, wherein:
the computerized device comprises a robotic device configured to execute the action within an environment comprising one or more objects characterized by one or more corresponding object motion parameters;
the executed action is characterized by a motion parameter of the robotic device; and
the executed action is configured based on a modification of the motion parameter based on a value associated with the corresponding object motion parameter.
18. The method of claim 6, wherein:
the computerized device comprises a household appliance configured to perform a cleaning task of a user premises; and
a state comprises information related to the premises.
19. The method of claim 18, further comprising:
loading another set of instructions which were previously configured to cause execution of another task by another computerized device;
wherein the loading the another set of instructions is triggered automatically by the computerized device based on a characteristic of the premises.
20. A non-transitory computer-readable storage medium having instructions embodied thereon to determine an association between a sensory context and an action indication for an appliance device, the instructions when executed by a processing apparatus cause the processing apparatus to:
determine a first sensory context version based on a first sensory modality;
determine a second sensory context version based on a second sensory modality;
when the second sensory context version occurs within a first time window from occurrence of the first sensory context version, assign the first sensory context version and the first context version as the sensory context; and
associate the sensory context with the action indication based on occurrence of the action indication within a second time window from at least one of the second sensory context version or the second sensory context version;
wherein the association is configured to enable automatic provision of a command to the appliance device based on an occurrence of the sensory context, the command configured to cause the appliance device to execute the action.
21. The non-transitory computer-readable storage medium of claim 20, where the instructions further cause the processing apparatus to:
determine the first sensory context based on a high pass filter operation version using a first sensory modality, the high pass filter operation characterized by a decay time scale;
where one or more data of the first sensory modality comprises a sequence of images; and
the decay time scale is at least 5 times longer than the time window.
22. The non-transitory computer-readable storage medium of claim 20, where the instructions further cause the processing apparatus to:
determine a first sensory context version comprising a transformation of individual ones of a sequence of input images to transformed images, the individual ones of the transformed images characterized by a first data rate that is at least 10 times lower than a second data rate of respective input images; and
where one or more data of the first sensory modality comprises a sequence of input images provided by a video camera.
23. Computerized apparatus, comprising:
sensory apparatus;
motive apparatus configured to move the at least one sensory apparatus within an environment, the environment being perceivable via the sensory apparatus;
neuromorphic computerized logic in data communication with the sensory apparatus and the motive apparatus, the computerized logic configured to adaptively learn at least one behavior relating to a context, the context relating at least in part to the environment, the adaptive learning comprising:
association of a first perception of the environment obtained from the sensory apparatus with the context;
association of a behavior with the context; and
subsequent implementation of the behavior when the context is determined to exist via at least one subsequent perception of the environment.
24. The computerized apparatus of claim 23, wherein:
the sensory apparatus comprises at least one visual band image sensor capable of generating images of objects in proximity to the computerized apparatus;
the first perception of the environment comprises at least one image of an object within the environment and having a first configuration; and
the association of the first perception with the context comprises association of the first configuration with a condition where a command is being given in order to invoke the behavior.
25. The computerized apparatus of claim 24, wherein the object comprises a human, the first configuration comprises a prescribed posture of the human, and the invoked behavior comprises causing the motive apparatus to stop.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A formulation comprising from about 0.05 to about 2.5 mg oglemilast or a pharmaceutically acceptable salt thereof, wherein the formulation provides an in vivo plasma profile comprising:
(i) a mean Cmax of more than about 2 ngmL,
(ii) a mean AUC0-24 of more than about 26 ng.hrmL and
(iii) a mean Tmax of about 0.25 or more hours.
2. The formulation of claim 1, wherein the formulation comprises about 0.05 mg oglemilast or a pharmaceutically acceptable salt thereof.
3. The formulation of claim 1, wherein the formulation comprises about 0.1 mg oglemilast or a pharmaceutically acceptable salt thereof and provides an in vivo plasma profile comprising:
(i) a mean Cmax of more than about 6 ngmL,
(ii) a mean AUC0-24 of more than about 100 ng.hrmL and
(iii) a mean Tmax of about 1 or more hours.
4. The formulation of claim 1, wherein the formulation comprises about 0.2 mg oglemilast or a pharmaceutically acceptable salt thereof, and provides an in vivo plasma profile comprising:
(i) a mean Cmax of more than about 12 ngmL,
(ii) a mean AUC0-24 of more than about 150 ng.hrmL and
(iii) a mean Tmax of about 1 or more hours.
5. The formulation of claim 1, wherein the formulation comprises about 0.4 mg oglemilast or a pharmaceutically acceptable salt thereof, and provides an in vivo plasma profile comprising:
(i) a mean Cmax of more than about 25 ngmL,
(ii) a mean AUC0-24 of more than about 240 ng.hrmL and
(iii) a mean Tmax of about 1 or more hours.
6. The formulation of claim 1, wherein the formulation comprises about 0.6 mg oglemilast or a pharmaceutically acceptable salt thereof, and provides an in vivo plasma profile comprising:
(i) a mean Cmax of more than about 40 ngmL,
(ii) a mean AUC0-24 of more than about 550 ng.hrmL and
(iii) a mean Tmax of about 1 or more hours.
7. The formulation of claim 1, wherein the formulation comprises about 0.8 mg oglemilast or a pharmaceutically acceptable salt thereof, and provides an in vivo plasma profile comprising:
(i) a mean Cmax of more than about 50 ngmL,
(ii) a mean AUC0-24 of more than about 650 ng.hrmL and
(iii) a mean Tmax of about 1 or more hours.
8. The formulation of claim 1, wherein the formulation comprises about 1.25 mg oglemilast or a pharmaceutically acceptable salt thereof, and provides an in vivo plasma profile comprising:
(i) a mean Cmax of more than about 95 ngmL,
(ii) a mean AUC0-24 of more than about 1200 ng.hrmL and
(iii) a mean Tmax of about 1 or more hours.
9. The formulation of claim 1, wherein the formulation comprises about 2.5 mg oglemilast or a pharmaceutically acceptable salt thereof, and provides an in vivo plasma profile comprising:
(i) a mean Cmax of more than about 150 ngmL,
(ii) a mean AUC0-24 of more than about 2400 ng.hrmL and
(iii) a mean Tmax of about 1 or more hours.
10. The formulation of claim 1, wherein the formulation comprises about 0.5 mg oglemilast or a pharmaceutically acceptable salt thereof, and provides an in vivo plasma profile comprising:
(i) a mean Cmax of more than about 4 ngmL,
(ii) a mean AUC0-24 of more than about 30 ng.hrmL and
(iii) a mean Tmax of about 1 or more hours.
11. The formulation of claim 1, wherein the formulation comprises about 0.1 mg oglemilast or a pharmaceutically acceptable salt thereof, and provides an in vivo plasma profile comprising:
(i) a mean Cmax of more than about 7 ngmL,
(ii) a mean AUC0-24 of more than about 120 ng.hrmL and
(iii) a mean Tmax of about 1 or more hours.
12. The formulation of claim 1, wherein the formulation comprises about 0.2 mg oglemilast or a pharmaceutically acceptable salt thereof, and provides an in vivo plasma profile comprising:
(i) a mean Cmax of more than about 14 ngmL,
(ii) a mean AUC0-24 of more than about 140 ng.hrmL and
(iii) a mean Tmax of about 1 or more hours.
13. The formulation of claim 1, wherein the formulation comprises about 0.4 mg oglemilast or a pharmaceutically acceptable salt thereof, and provides an in vivo plasma profile comprising:
(i) a mean Cmax of more than about 28 ngmL,
(ii) a mean AUC0-24 of more than about 260 ng.hrmL and
(iii) a mean Tmax of about 1 or more hours.
14. The formulation of claim 1, wherein the formulation comprises about 0.6 mg oglemilast or a pharmaceutically acceptable salt thereof, and provides an in vivo plasma profile comprising:
(i) a mean Cmax of more than about 45 ngmL,
(ii) a mean AUC0-24 of more than about 600 ng.hrmL and
(iii) a mean Tmax of about 1 or more hours.
15. The formulation of claim 1, wherein the formulation comprises about 0.8 mg oglemilast or a pharmaceutically acceptable salt thereof, and provides an in vivo plasma profile comprising:
((i) a mean Cmax of more than about 50 ngmL,
(ii) a mean AUC0-24 of more than about 600 ng.hrmL and
(iii) a mean Tmax of about 1 or more hours.
16. The formulation according to claim 1, wherein about 20% or more of the oglemilast is amorphous.
17. The formulation according to claim 1, wherein about 40% or more of the oglemilast is amorphous.
18. The formulation according to claim 1, wherein about 60% or more of the oglemilast is amorphous.
19. The formulation according to claim 1, wherein about 80% or more of the oglemilast is amorphous.
20. The formulation according to claim 1, wherein about 90% or more of the oglemilast is amorphous.
21. A method of treating an inflammatory or allergic condition comprising administering to a patient in need thereof a formulation according to claim 1.
22. The method of claim 21, wherein the condition is asthma, bronchial asthma, chronic obstructive pulmonary disease, allergic rhinitis, eosinophilic granuloma, nephritis, rheumatoid arthritis, cystic fibrosis, chronic bronchitis, multiple sclerosis, Crohns disease, psoraisis, uticaria, adult vernal cojunctivitis, respiratory distress syndrome, rhematoid spondylitis, osteoarthritis, gouty arthritis, uteltis, allergic conjunctivitis, inflammatory bowel conditions, ulcerative colitis, eczema, atopic dermatitis or chronic inflammation.
23. The method of claim 22, wherein the condition is asthma.
24. The method of claim 22, wherein the condition is COPD.
25. The method of claim 22, wherein the condition is rheumatoid arthritis.
26. A substantially pure amorphous form of a compound of formula (I):
wherein
R1, R2 and R3 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, nitro, \u2014OH, cyano, formyl, acetyl, halogen, protecting groups, \u2014C(O)Ra, \u2014C(O)ORa, \u2014C(O)NRaRa, \u2014S(O)qRa, S(O)qNRaRa, \u2014NRRa, \u2014ORa, and \u2014SRa,
or two R3 substituents ortho to each other may be joined to a form a saturated or unsaturated 3-7 membered cyclic ring which may optionally include up to two heteroatoms which may be same or different selected from O, NRa and S;
R4 is \u2014NR5R6; wherein R5 and R6 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, nitro, \u2014OH, cyano, halogen, \u2014C(O)Ra, \u2014C(O)ORa, \u2014C(O)NRaRa, \u2014S(O)qRa, \u2014S(O)qNRaRa, \u2014C(\u2550NRa)Ra, \u2014C(\u2550NRa)NRaRa, \u2014C(\u2550S)NRaRa, \u2014C(\u2550S)Ra, \u2014N\u2550C(RaRa)\u2014, \u2014NRaRa, \u2014ORa, \u2014SRa, and protecting groups,
or R5 and R6 may be joined to a form a saturated or unsaturated 3-7 membered cyclic ring, which may optionally include up to two heteroatoms which may be same or different selected from O, NRa and S;
Ar is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclic ring and substituted or unsubstituted heteroaryl ring;
X is selected from the group consisting of O, S(O)q and NRa;
Y is selected from the group consisting of \u2014C(O)NR7, \u2014NR7S(O)q, \u2014S(O)qNR7 and \u2014NR7C(O);
each Z is independently C or N;
R7 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, hydroxyl, \u2014ORa, substituted or unsubstituted aryl, and substituted or unsubstituted heterocyclic ring;
p is chosen from O and S;
m represents 0-3; n represents 1-4; q represents 0, 1 or 2; and
Ra is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, nitro, \u2014OH, cyano, formyl, acetyl, halogen, protecting groups, \u2014C(O)Ra, \u2014C(O)ORa, \u2014C(O)NRaRa, \u2014S(0)qRa, \u2014S(O)qNRaRa, \u2014NaRa, \u2014ORa, and \u2014SRa.
27. The compound of claim 26, wherein about 40% or more of the compound is amorphous.
28. The compound of claim 26, wherein about 60% or more of the compound is amorphous
29. The compound of claim 26, wherein about 75% or more of the compound is amorphous
30. The compound of claim 26, wherein about 80% or more of the compound is amorphous
31. The compound of claim 26, wherein about 90% or more of the compound is amorphous.
32. The compound of claim 26, wherein the compound comprises oglemilast.
33. A formulation comprising about 20% or more of an amorphous compound of formula (I):
wherein
R1, R2 and R3 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, nitro, \u2014OH, cyano, formyl, acetyl, halogen, protecting groups, \u2014C(O)Ra, \u2014C(O)ORa, \u2014C(O)NRaRa, \u2014S(O)qRa, S(O)qNRaRa, \u2014NRRa, \u2014ORa, and \u2014SRa,
or two R3 substituents ortho to each other may be joined to a form a saturated or unsaturated 3-7 membered cyclic ring which may optionally include up to two heteroatoms which may be same or different selected from O, NRa and S;
R4 is \u2014NR5R6; wherein R5 and R6 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, nitro, \u2014OH, cyano, halogen, \u2014C(O)Ra, \u2014C(O)ORa, \u2014C(O)NRaRa, \u2014S(O)qRa, \u2014S(O)qNRaRa, \u2014C(\u2550NRa)Ra, \u2014C(\u2550NRa)NRaRa, \u2014C(\u2550S)NRaRa, \u2014C(\u2550S)Ra, \u2014N\u2550C(RaRa)\u2014, \u2014NRaRa, \u2014ORa, \u2014SRa, and protecting groups,
or R5 and R6 may be joined to a form a saturated or unsaturated 3-7 membered cyclic ring, which may optionally include up to two heteroatoms which may be same or different selected from O, NRa and S;
Ar is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclic ring and substituted or unsubstituted heteroaryl ring;
X is selected from the group consisting of O, S(O)q and NRa;
Y is selected from the group consisting of \u2014C(O)NR7, \u2014NR7S(O)q, \u2014S(O)qNR7 and \u2014NR7C(O);
each Z is independently C or N;
R7 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, hydroxyl, \u2014ORa, substituted or unsubstituted aryl, and substituted or unsubstituted heterocyclic ring;
p is chosen from O and S;
m represents 0-3; n represents 1-4; q represents 0, 1 or 2; and
Ra is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, nitro, \u2014OH, cyano, formyl, acetyl, halogen, protecting groups, \u2014C(O)Ra, \u2014C(O)ORa, \u2014C(O)NRaRa, \u2014S(O)qRa, \u2014S(O)qNRaRa, \u2014NaRa, \u2014ORa, and \u2014SRa.
34. The formulation of claim 33, wherein about 40% or more of the compound of formula (I) is amorphous.
35. The formulation of claim 33, wherein about 60% or more of the compound of formula (I) is amorphous.
36. The formulation of claim 33, wherein about 75% or more of the compound of formula (I) is amorphous.
37. The formulation of claim 33, wherein about 80% or more of the compound of formula (I) is amorphous.
38. The formulation according to claim 33, wherein about 90% or more of the compound of formula (I) is amorphous.
39. The formulation of claim 33, wherein the formulation comprises oglemilast.
40. The formulation of claim 39, further comprising oglemilast sodium.
41. A formulation comprising about 20% or more amorphous oglemilast, wherein the formulation provides an in vivo plasma profile comprising:
(i) a mean Cmax of more than about 2 ngmL,
(ii) a mean AUC0-\u221e of less than about 15,000 ng hml, and
(iii) a mean Tmax of more than about 0.25 hour.
42. The formulation of claim 41, wherein about 40% or more of the oglemilast is amorphous.
43. The formulation of claim 41, wherein about 60% or more of the oglemilast is amorphous.
44. The formulation of claim 41, wherein about 80% or more of the oglemilast is amorphous.
45. The formulation of claim 41, wherein about 90% or more of the oglemilast is amorphous.
46. The formulation of claim 41, comprising from about 0.05 to about 2.5 mg oglemilast.
47. The formulation of claim 41, comprising from about 0.1 to about 2.5 mg oglemilast.
48. The formulation of claim 41, comprising from about 0.2 to about 1 mg oglemilast.
49. A formulation comprising 0.8 mg oglemilast wherein about 20% or more of the oglemilast is amorphous and the formulation provides an in vivo plasma profile comprising:
(i) a mean Cmax of more than about 38 ngmL,
(ii) a mean AUC0-\u221e0 of more than about 440 ng hml, and
(iii) a mean Tmax of more than about 0.25 hours.
50. (canceled)
51. The formulation of claim 49, wherein the formulation has a dissolution rate of the active ingredient of about 85% or more in about 60 minutes or less.
52. The formulation of claim 49, wherein the formulation has a dissolution rate of the active ingredient of about 80% or more in about 60 minutes or less.
53. A formulation comprising (i) solubilized form of oglemilast and (ii) one or more excipients wherein the one or more excipients are present in an amount sufficient to retard formation of crystalline oglemilast.
54. The formulation of claim 53 in the form of a solution or a suspension.
55. The formulation of claim 54, wherein the pH of the solution is greater than about 7.
56. The formulation of claim 53, where the one or more excipients are selected from povidone, polyethylene glycol, celluloses, starches, povidone-vinyl acetate copolymers, cyclodextrins, disaccharides, polysaccharides and combinations thereof.
57. The formulation of claim 56, where the one or more excipients are selected from povidone, polyethylene glycol, hydroxypropyl methylcellulose, hydroxypropyl cellulose, pregelatinized starch, povidone-vinyl acetate copolymers hydroxypropyl beta cyclodextrin, sucrose, trehalose, dextran, and combinations thereof.
58. The formulation of claim 57, wherein the excipient is povidone.
59. The formulation of claim 33, wherein the formulation is adapted for oral administration.
60. The formulation of claim 59, in the form of a pill, tablet, capsule, dragee, powder, caplet, troche, elixir, oral suspension, solution, dry powder suspension, syrup, wafer, lozenge, orally disintegrating film, or orally disintegrating tablet.
61. The formulation of claim 60, in the form of a tablet, capsule, solution or oral suspension.
62. A method of treating an inflammatory or allergic condition comprising administering to a patient in need thereof a formulation according to claim 33.
63. The method of claim 62, wherein the inflammatory or allergic condition is chosen from asthma, bronchial asthma, chronic obstructive pulmonary disease, allergic rhinitis, eosinophilic granuloma, nephritis, rheumatoid arthritis, cystic fibrosis, chronic bronchitis, multiple sclerosis, Crohns disease, psoraisis, uticaria, adult vernal cojunctivitis, respiratory distress syndrome, rhematoid spondylitis, osteoarthritis, gouty arthritis, uteltis, allergic conjunctivitis, inflammatory bowel conditions, ulcerative colitis, eczema, atopic dermatitis and chronic inflammation.
64. The method of claim 63, wherein the condition is asthma.
65. The method of claim 63, wherein the inflammatory or allergic condition is COPD.
66. The method of claim 63, wherein the inflammatory condition is rheumatoid arthritis.
67. A formulation comprising about 20% solubilized oglemilast, wherein the formulation provides an in vivo plasma profile comprising:
(i) a mean Cmax of more than about 2 ngmL,
(ii) a mean AUC0-\u221e of less than about 15,000 ng hml, and
(iii) a mean Tmax of more than about 0.25 hour.